Egalet Corporation (NASDAQ:EGLT) Files An 8-K Other Events
Item 8.01 – Other Events
On June6, 2017, Egalet Corporation issued a press release
announcing that one of the largest payers in the United States
will provide coverage of ARYMO ER (morphine sulfate)
extended-release tablets for oral use CII, a copy of which is
filed herewith as Exhibit99.1 and incorporated herein by
reference.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNumber |
|
Description |
|
99.1 |
Press Release, dated June6, 2017. |
About Egalet Corporation (NASDAQ:EGLT)
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company’s product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company’s product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company’s product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company’s product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
